Abstract
Basal glucose control is commonly maintained by a single, once-daily administration of insulin through subcutaneous injection or a continuous pump-infusion. Insulin icodec, a novel ultralong-acting lipidated analog validates the concept of a once-weekly basal injection that is less burdensome, yet equally safe and efficacious as conventional once-daily treatment.
Publication types
-
Introductory Journal Article
MeSH terms
-
Blood Glucose
-
Diabetes Mellitus, Type 2 / drug therapy*
-
Diabetes Mellitus, Type 2 / metabolism
-
Drug Administration Schedule
-
Humans
-
Hypoglycemic Agents / administration & dosage
-
Hypoglycemic Agents / chemistry
-
Hypoglycemic Agents / therapeutic use*
-
Infusions, Subcutaneous
-
Insulin / administration & dosage
-
Insulin / analogs & derivatives
-
Insulin / therapeutic use*
Substances
-
Blood Glucose
-
Hypoglycemic Agents
-
Insulin